[1]
G. Di Minno and R. Ravasio, “Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy”, Grhta, vol. 8, no. 1, pp. 43–52, Apr. 2021.